UMN Pharma Inc. announced that it has reached a construction agreement with IHI Plant Engineering Corporation, an affiliate of IHI Corporation. This is the first step toward the construction of a facility to manufacture UMN-0501, UMN's pandemic influenza vaccine under development, produced using a cell culture technique.

News release PDF file.  (108K)

In order to view this file, you will need to have the following plug-in installed.